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Cell non-autonomous mechanism of cancer
predispositionPredisposition to breast and extrauterine Müllerian carcinomas in BRCA1mutation carriers is due to a combina-
tion of cell-autonomous consequences of BRCA1 inactivation on cell cycle homeostasis superimposed on cell-
nonautonomous hormonal factors magniﬁed by the effects of BRCA1mutations on hormonal changes associated
with themenstrual cycle.Weused theMüllerian inhibiting substance type 2 receptor (Mis2r) promoter and a trun-
cated form of the Follicle stimulating hormone receptor (Fshr) promoter to introduce conditional knockouts of
Brca1 and p53 not only in mouse mammary and Müllerian epithelia, but also in organs that control the estrous
cycle. Sixty percent of the double mutant mice developed invasive Müllerian and mammary carcinomas. Mice
carrying heterozygous mutations in Brca1 and p53 also developed invasive tumors, albeit at a lesser (30%) rate,
in which the wild type alleles were no longer present due to loss of heterozygosity. While mice carrying hetero-
zygousmutations in both genes developedmammary tumors, none of themice carrying only a heterozygous p53
mutation developed such tumors (P b 0.0001), attesting to a role for Brca1mutations in tumor development. This
mousemodel is attractive to investigate cell-nonautonomousmechanisms associatedwith cancer predisposition
in BRCA1mutation carriers and to investigate the merit of chemo-preventive drugs targeting such mechanisms.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Extra-uterine high-grade serous Müllerian carcinomas, which include
cancers originating in either the fallopian tubes or endosalpingiosis
(Dubeau, 2008; Dubeau and Drapkin, 2013), are the most lethal gyneco-
logical cancers while carcinomas of the breast are themost common can-
cer inwomen (Boyle et al., 2008). There is considerable overlap in the risk
factors associatedwith both diseases. For example, menstrual cycle activ-
ity is themost important risk factor for the sporadic formsof bothdiseases
while germline BRCA1 or BRCA2mutations are the most important cause
of the familial forms (Whittemore et al., 1992; Brose et al., 2002; Pike
et al., 2004). An understanding of the underlying mechanisms mediating
cancer risk for both diseases could have a signiﬁcant impact on theirmor-
bidity and mortality by leading to the development of preventive strate-
gies targeting these mechanisms speciﬁcally.
Existing mouse models for serous extra-uterine Müllerian
(previously referred to as serous ovarian) carcinomas (Dubeau, 2008;1 Eastlake Avenue, Los Angeles,
. This is an open access article underDubeau and Drapkin, 2013), are based on forced expression of selected
oncogenes, often combined with homozygous knockouts of BRCA1 or
BRCA2 or other relevant tumor suppressor genes in a tissue-speciﬁc
manner (Miyoshi et al., 2002; Orsulic et al., 2002; Connolly et al.,
2003; Flesken-Nikitin et al., 2003; Dinulescu et al., 2005;
Clark-Knowles et al., 2007; Szabova et al., 2012; Perets et al., 2013).
None of these models, to our knowledge, are associated with predispo-
sition to both reproductive and mammary cancers. These models have
led to signiﬁcant progress in establishing the role of the targeted
genes or pathways in cancer development and elucidating their intra-
cellular activity, but were not designed to investigate the interplay be-
tween environmental/hormonal and genetic factors. In addition,
although heterozygous germline BRCA1/2mutations are strongly asso-
ciated with cancer predisposition in both organs in human, the current
models are invariably based on homozygous inactivation of these genes,
a condition that is never present in the human germline. Even when re-
stricted to speciﬁc organs, such homozygous lesions may lead to devel-
opment defects in these organs (Xu et al., 1999; Kim et al., 2006),
diminishing their relevance to human. The higher penetrance of homo-
zygous mutations may also override the inﬂuence of environmental orthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tionwith genetic factors. Finally, there is strong evidence, both from an-
imal and human studies (Chodankar et al., 2005; Hong et al., 2010;
Widschwendter et al., 2013), that BRCA1mutations lead to cancer pre-
disposition not only via cell-autonomous mechanisms, but also via al-
terations in hormone producing cells that inﬂuence, from a distance,
the cells from which ovarian and breast cancers develop. This conclu-
sion is strengthened by the fact that menstrual cycle activity has a
strong inﬂuence on risk of breast and extra-uterine Müllerian carcino-
ma, even in individuals with strong genetic predisposition such as
Brca1 mutation carriers (Narod et al., 1998). Current animal models
based on inactivation of Brca1 to induce the development of invasive
cancers do not recapitulate such cell-nonautonomous mechanisms.
We sought to develop a mouse model for breast and extra-uterine
Müllerian cancer predisposition based on conditional inactivation of
Brca1 not only in these organs, but also in hormone producing cells
that regulate the menstrual cycle, including ovarian granulosa cells
and the anterior pituitary gland, in order to mimic both the genetic
background and the cell-nonautonomous conditions associated with
strong predisposition to these cancers in humans. Transgenic constructs
driving expression of Cre recombinase under the control of a combina-
tion of cell-speciﬁc promoters active in the various tissues of interest
were introduced in mice carrying ﬂoxed alleles not only in Brca1, but
also in p53, a gene mutated in almost all human cancers associated
with the BRCA1 mutation carrier state (Ahmed et al., 2010). The cell-
speciﬁc promoters used included a previously characterized truncated
form of the Follicle stimulating hormone receptor (Fshr) promoter
(Griswold et al., 1995; Chodankar et al., 2005) and the Müllerian
inhibiting substance receptor type 2 (Mis2r) promoter (Josso et al.,
2001; Connolly et al., 2003). The latter is expressed in the Müllerian
ducts during embryological development, which later differentiate
into internal reproductive organs including fallopian tubes, uterus, cer-
vix, and a portion of the vagina, as well as other extra-uterine structures
carrying increased cancer risk in BRCA1 mutation carriers such as
endosalpingiosis.Mis2r promoter is also active inmammary epithelium
(Segev et al., 2001).
2. Materials and Methods
2.1. Ethics Statement
All studies with experimental animals were approved by and per-
formed under supervision of the University of Southern California Insti-
tutional Animal Care and Use Committee.
2.2. Source and Handling of Experimental Animals
Animals were housed in a pathogen-free environment at the Vivaria
facility of the USC Health Sciences campus. All facilities received daily
monitoring and care from Vivaria staff under the supervision of a veter-
inarian. A maximum of 5 mice were housed per cage. Assignment to
each experimental group was based on genotype. Euthanasia was
achieved by cervical dislocation after the mice were made unconscious
from exposure to CO2.
2.3. Source or Generation and Characterization of Transgenic Mice and
Constructs
The generation of Fshr-Cre transgenic mice was described earlier
(Chodankar et al., 2005). This mouse is available from Jackson laborato-
ry mouse repository (JAX Stock 24926, B6;D2-Tg(Fshr-Cre)1Ldu/J).
Primers used for documenting the presence of the transgene were de-
scribed (Chodankar et al., 2005). A 1.2 kb fragment of theMis2r promot-
er provided by Dr. Connolly (Connolly et al., 2003) from the Fox Chase
Cancer Center was placed upstream of either a 1.2 kb fragment of the
β-galactosidase gene or a 1.1 kb Cre recombinase gene fragment,followed by a 2.1 kb SV40 poly A tail. For theMis2r-Hsp68-lacZ construct,
a 0.9 kb fragment of the Hsp68 minimal promoter was also placed
downstream of the Mis2r promoter in a Bluescript KS vector backbone
(Brugger et al., 2004). The linear puriﬁed construct was injected into
the pronuclei of fertilized oocytes of B6D2F1 animals and the injected
embryos were transferred into pseudopregnant mice according to stan-
dard protocols. Pupswere analyzed for thepresence of the Cre transgen-
ic construct by PCR ampliﬁcation of tail DNA using 5′-CTCTGGTGTAGC
TGATGATC-3′ as forward primer and 5′-TAATCGCCATCTTCCAGCAG-3′
as reverse primer. For detection of the Mis2r-Hsp68-LacZ construct we
used a forward primer complementary to the Mis2r sequence (5′-
ACAGAGACCGGGATAGGACAGA-3′) and a reverse primer complemen-
tary to the lacZ sequence (5′-CAAACGGCGGATTGACCGTA-3′). Founder
mice were backcrossed with B6 animals to generate transgenic lines.
Two independent transgenic lines were generated using each construct.
Mis2r-Cre transgenicmicewere crossedwith either one of two R26R re-
porter lines, one carrying a LacZ gene whose expression requires exci-
sion of loxP-ﬂanked stop sequences (R26RLacZ) and the other carrying
a similar ﬂoxed insert within the coding sequence for Green Fluores-
cence Protein (R26RGFP). Signal to noise ratio and tissue speciﬁc expres-
sionwere evaluated and compared in the various lines. The onewith the
highest level of tissue speciﬁc transgene expressionwas selected. Distri-
bution of promoter activity was similar in transgenic lines generated in-
dependently from the same transgenic constructs.2.4. Source and Genotyping of Mice Carrying Floxed Alleles
The mouse line carrying a ﬂoxed p53 allele was purchased from the
Jackson laboratory mouse repository (stock number 008,462). The
unrearranged ﬂoxed allele was detected using 5′-GGTTAAACCCAGCT
TGACCA-3′ as forward PCR primer and 5′- GGAGGCAGAGACAGTTGG
AG-3′ as reverse primer. The Cre-driven rearrangement was detected
using 5′-CACAAAAACAGGTTAAACCCA-3′ as forward PCR primer and
5′-GAAGACAGAAAAGGGGAGGG-3′ as reverse primer. The mouse line
carrying a ﬂoxed Brca1 allele targeting Brca1 exon 11 was obtained
from Chuxia Deng of the National Cancer Institute and genotyped as re-
ported earlier (Chodankar et al., 2005).2.5. Cre-mediated Recombination Analysis of R26R
Demonstration of β-galactosidase recombination was achieved ﬁrst
by enzymatic ampliﬁcation of DNA from the organs of interest using
5′-AAAGTCGCTCTGAGTTGTTAT-3′ and 5′-CAAACGGCGGATTGACCGTA-
3′ as forward and reverse primers, respectively, followed by re-
ampliﬁcation with 5′- AGTAAGGGAGCTGCAGTGGAGTA-3′ and 5′-
ATGGGATAGGTTACGTTGGTGTAGAT-3′ as nested forward and reverse
primers. Forward and reverse primers for detection of the unrearranged
sequence were 5′- TTGCGCAGCTGTGCTCGACG-3′ and 5′-AAGGCGATGC
GCTGCGAATC-3′.2.6. Colorimetric β-galactosidase Assay
Tissue samples were ﬁxed in cold 4% paraformaldehyde, washed
with cold phosphate buffered saline and dehydrated in 30% sucrose.
Ten-micron cryostat sections were ﬁxed in cold 0.2% glutaraldehyde.
The sections were washed with cold phosphate buffered saline, prein-
cubated in the same buffer containing 2 mM magnesium chloride,
0.01% sodium deoxycholate, 0.02% Nonidet P-40 for 10 min, and incu-
bated overnight at 37 °C in 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6, 2 mM
MgCl2, 0.01% sodium deoxycholate, 0.02% Nonidet P-40, 1 mg/ml
X-Gal (Sigma-Aldrich, St. Louis, MO, cat# B4252) in phosphate buffer
saline [pH 7.4]. The sections were postﬁxed in 4% paraformaldehyde
and counter stained with Nuclear Fast Red (Sigma-Aldrich, cat#
229113).
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All mice were observed over a period of 24 months unless they de-
veloped a palpable tumor or showed signs of severe distress, such as
due to underlying inﬂammatory conditions or to cancers outside the re-
productive tract or the mammary glands such as lymphomas. All mice
were fully necropsied. Age of detection of mammary tumors represents
the age at which a palpable tumor was ﬁrst detected. As for the 3 extra-
uterine Müllerian cancers, age of detection refers to the age at which
they were discovered incidentally at necropsy, including in a mouse
that had reached the age of 24 months (accounting for one case), in a
mouse that needed to be euthanized because of severe distress (one
case), and in amouse inwhich amammary tumor had become palpable
(one case).
2.8. Fluorescence Imaging
Green ﬂuorescence in renal tissue sections was visualized with a
Leica DMI 6000 inverted microscope and a 63× glycerol immersion ob-
jective (NA 1.4) and imaged using a Leica TCS SP5 AOBS confocal ﬂuo-
rescence imaging system powered by a Chameleon Ultra-II MP laser
(Coherent Inc.) or a 488 nmAr laser (LeicaMicrosystems). Fluorescence
excitation and detector settings were the same for imaging transgenic
and wild type tissue sections.
2.9. Laser Capture Microdissection
We used Arcturus XT-TI LCM System purchased from Arcturus Bio-
Science Inc., Mountain View, California.
2.10. Immunohistochemical Detection of Estrogen and Progesterone
Receptor Proteins
ERα (HC-20) and PR(AB-52) were purchased from Santa Cruz Bio-
technology (catalogs #SC-543 and #SC-810, respectively, Santa Cruz,
CA). Both antibodies were diluted 1:400 in 2.5% horse serum (in phos-
phate buffer saline) and hybridized to tissue sections overnight at 4 °C.
Frozen tissue sections were ﬁxed in 4% paraformaldehyde for 10 min
followed by three 3-minwashes in phosphate buffer saline, one 5min in-
cubation in 3% H2O2, and a 1-h incubation in 2.5% horse serum before in-
cubation with the primary antibodies. The ImmPRESS Excel Staining kit,
anti-rabbit Ig (catalog #MP-7601, Vector Laboratories, Burlingame, CA)
was used for ERα according to manufacturer's instructions. Goat anti-
mouse secondary antibody (catalogs # A11001, Invitrogen, Grand Island,
NY. 1:400 in 2.5% horse serum, 1 h) was used as secondary antibody for
PR immunostaining.
2.11. Her-2/neu Protein Detection by Western Blotting
Cells and tissueswere lysed in triton lysis buffer (25mMsodiumphos-
phate, 150mMsodium chloride, 1% Triton X-100, 5mMEDTA, 50mM so-
dium ﬂuoride, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl
ﬂuoride, 5 μM pepstatin A, 10 μg/ml aprotinin, 10 μg/ml leupeptin,
25 μM phenylarsine oxide) for 30 min at 4 °C. Aliquots of 50 micrograms
in Laemmli bufferwere heated in boilingwater for 5min, electrophoresed
on 10% polyacrylamide gels, and transferred to PVDFmembranes (Biorad,
Hercules, CA). The membranes were treated for one hour at room tem-
perature with blocking buffer (5% milk proteins, 0.05% Tween 20 in
Tris buffer, pH 8.1) and hybridized overnight in the same buffer
containing 1:500 dilutions of rabbit anti-Neu (SC-284) and rabbit
anti-GAPDH (SC-25,778) (both antibodies from Santa Cruz Biotech-
nology, Santa Cruz, CA). The membranes were washed 3 times for
5 min with 0.05% Tween-20 in Tris-Cl, pH 8.1 and probed with a
1:2000 dilution of goat anti-rabbit IgG-HRP (Santa Cruz Biotechnol-
ogy, SC-2004) in blocking buffer for 1 h at room temperature. The
membranes were then washed 3 times for 10 min in 0.05% Tween20 in Tris buffer, pH 8.1 and incubated with ECL Western blot Sub-
strate (ThermoFisher, Grand Island, NY, Catalog Number 32106) for
1 min before being exposed to X-ray ﬁlms (Denville Scientiﬁc,
Holliston, MA, Catalog Number E3012) for 5–10 min and developed.
3. Results
3.1. Distribution of Mis2r Promoter Expression in Tissues Derived From the
Müllerian Ducts
3.1.1. Reproductive Organs
We ﬁrst sought to verify that the Mis2r promoter in our proposed
transgenic construct was active in tissues embryologically derived
from the Müllerian ducts, the only anatomical structure currently
known to express this receptor during development. Reproductive
organs were obtained from 2-month old transgenic mice expressing
β-galactosidase under the control of this promoter and stained for
LacZ (Fig. 1a–d). The strong color seen over the cervix, uterine horns,
and oviducts in the whole mount photograph shown in Fig. 1a, indica-
tive of LacZ positivity, attests to the activity of the promoter in these or-
gans at the time they were harvested. The ovaries, which are not
embryologically derived from the Müllerian ducts, were also strongly
positive. A cross section through a uterine horn in panel 1b shows
LacZ positivity in the endometrial lining while the photograph in
panel 1c shows positivity in the epithelial lining at the boundary be-
tween the cervix and upper vagina. Panel 1d shows absence of LacZ
staining in a segment of uterine horn with attached oviduct and ovary
from a non-transgenic littermate control.
3.1.2. Endosalpingiosis
Wesuggested earlier that structures derived from themost proximal
portion of the Müllerian ducts, such as endosalpingiosis and others, are
an important site of origin of tumors previously classiﬁed as ovarian car-
cinomas, including the high-grade serous subtype associated with the
BRCA1 mutation carrier state (Dubeau, 1999, 2008). We therefore
sought to determine whether or not such structures express the
Mis2r promoter in order to conﬁrm their Müllerian origin and further
evaluate the merit of this promoter as a driver of conditional Brca1
inactivation in a mouse model for extra-uterine Müllerian tumor de-
velopment. Staining intensity for LacZ in endosalpingiotic foci from
mice carrying the Mis2r-Hsp68-LacZ transgene was weak and not
convincingly above background levels. We therefore used a trans-
genic line expressing Cre recombinase under the control of Mis2r,
which we crossed with the R26R line carrying the β-Galactosidase
gene inactivated by a ﬂoxed insert containing a termination codon.
Foci of endosalpingiosis, such as shown in Fig. 1e from a 3 day-old
mouse, were obtained by laser capture microdissection and the pres-
ence or absence of Cre-mediated rearrangement was evaluated by
PCR. A microdissected segment of uterine horn was used as positive
control while microdissected ovarian surface epitheliumwas used as
negative control. The results (Fig. 1f) conﬁrmed that such rearrange-
ment had taken place in the uterine horn and in endosalpingiosis
while ovarian surface epithelium, previously regarded as the site of
origin of most tumors classiﬁed as ovarian carcinoma, which we
now classify as extra-uterine Müllerian carcinomas (Dubeau, 2008;
Dubeau and Drapkin, 2013), showed no evidence of Cre-mediated
rearrangement.
3.1.3. Renal Collecting System
A segment of the renal collecting ducts consistently stained positive
for LacZ in R26R;Mis2r-Cre female, but not male mice as illustrated in
Fig. 2a. These results are not due to endogenous LacZ activity in renal tis-
sues because a similar conclusion was reached when we used a R26R
mouse line where the β-Galactosidase sequence was replaced by that
for Green Fluorescence Protein containing a ﬂoxed insert with a stop
codon, allowing us to evaluate Mis2r promoter activity based on
Fig. 1.Mis2r promoter expression in tissues embryologically derived from theMüllerian ducts. a–d: Reproductive organs from 2-month oldMis2r-Hsp68-LacZ transgenic mice and litter-
mate controls were stained for LacZ, resulting in either green or blue reaction products. (a): Uterine horns (arrows) with attached ovaries from a transgenic animal. (b): Cross-section of
uterine horns from the specimen shown in a. (c): Cross-section of upper part of vaginawith attached segments of both uterine horns of a transgenic animal. (d): Segment of a uterine horn
with attached ovary from a non-transgenic control. Scale bars: 1 mm. (e): Histological photograph of an ovary (long arrow) with adjacent uterine horn (short arrow) and foci of
endosalpingiosis (rectangle) from a 2 day oldMis2r-Cre;R26RLacZmouse stained with hematoxylin and eosin. Scale bar: 200 μm. Tissues of interest were subjected to laser capture micro-
dissection. DNAwas extracted and enzymatically ampliﬁedusing PCR primers speciﬁc for either the rearrangedor the unrearranged LacZ allele. The PCR productswere electrophoresed on
agarose gels and visualized under UV in order to examine the state of Cre-mediated rearrangement in each tissue (f).
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mediated rearrangements are transmitted to daughter cells during mi-
tosis, the presence of such rearrangements in either R26RLacZ or
R26RGFP mice indicates that the Mis2r promoter has been active in
renal collecting ducts or their embryological precursors at an undeter-
mined time point before the mice were harvested, but does not neces-
sarily reﬂect activity of this promoter at the time of euthanasia.
Indeed, no renal tissue stained positive for LacZ in the Mis2r-Hsp68-
LacZ line in either gender. The presence of gender-speciﬁc, Cre-
mediated rearrangement in microdissected sections of histological
preparation of renal tissue was also conﬁrmed by PCR (Fig. 2c). These
results strongly suggest a physical link between the Müllerian ducts
and the renal collecting system early in development. This conclusionis supported by an earlier report that theWolfﬁan ducts, the precursors
of fetal (mesonephros) and adult (metanephros) renal systems, are in
close relationship to each other in 12.5-day old mouse embryos
(Kobayashi et al., 2003).
3.2. Distribution of Mis2r Promoter Expression in Tissues not Derived From
the Müllerian Ducts
3.2.1. Ovaries
Strong LacZ positivity was seen over whole mounts of ovaries from
Mis2r-Hsp68-LacZmice in Fig. 1. We further investigatedMis2r promot-
er activity in this organ using R26Rmice harboring theMis2r-Cre trans-
gene. As shown in Fig. 3, ovaries subjected to such staining procedures
Fig. 2.Gender-speciﬁc expression ofMis2r in renal collecting ducts. Pelvic and lower abdominal tissues frommale and female newbornR26RLacZ (a) or R26RGFP (b) reportermice that either
carried or did not carry theMis2r-Cre transgene were exenterated and embedded as whole mounts, sectioned with a microtome, subjected to the LacZ staining protocol (a) or to ﬂuores-
cent light (b), and examined by light microscopy. Tissue sections in (a) were counterstained with Nuclear Fast Red. Scale bars: 500 μm. (c): DNA was extracted from the kidneys of new-
bornMis2r-Cre;R26RLacZ transgenic mice and from littermates lacking theMis2r-Cre transgene. DNA extracted from the uterus ofMis2r-Cre;R26RLacZmice was used as positive control. The
presence or absence of rearrangement of the β-galactosidase gene was documented by enzymatic ampliﬁcation with the same primers used in Fig. 1f followed by electrophoresis on 1%
agarose gels containing ethidium bromide and visualization of the PCR products under UV.
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with earlier reports of Mis2r expression in post-natal ovaries
(Baarends et al., 1995). We suspected that LacZ positivity in ovarian
follicles is not due to an embryological link between these follicles
and the Müllerian ducts, but instead indicates acquisition of Mis2r
expression during ovarian follicular differentiation. Although evi-
dence of Cre-mediated rearrangement of the R26R allele could be de-
tected by PCR as early as 3 days postnatally in R26R;Mis2r-Cre mice,
no such rearrangement was detectable prenatally (Fig. 3c) in sup-
port of our hypothesis.
3.2.2. Mammary Gland
Strong LacZ positivity was also observed in the mammary glands
of adult Mis2r-Hsp68-LacZ mice (Fig. 4), in support of earlier studies
performed on adult human mammary glands (Segev et al., 2001).
The presence of a physical interaction between mammary ducts
and Müllerian ducts during development is highly unlikely given
that the former are located outside the coelomic cavity. However, ev-
idence of Cre-mediated rearrangement in the mammary glands of
R26R;Mis2r-Cre mice was observed even in newborn animals
(Fig. 4c–e), strongly suggesting that mammary ducts express Mis2r
during their development, perhaps accounting for hormone-
independent anatomical differences between male and female
breasts.3.3. Distribution of Fshr Promoter Expression in the Mammary Gland
Partial information on the distribution of activity of a truncated form
of Fshr, which we previously used to investigate cell non-autonomous
consequences of Brca1 abnormalities, was reported earlier (Chodankar
et al., 2005). We sought to expand these studies to investigate the ex-
pression status of this receptor in the mammary gland in order to fur-
ther characterize our proposed mouse model. The results of Fig. 4g,
which show a LacZ stain of an adult mammary gland obtained from
Fshr-Cre;R26Rmouse, clearly show expression in the mammary gland.
Given earlier reports that this promoter, which is also active in ovarian
granulosa cells, is not active in the fallopian tubes, we conclude that a
Brca1 gene knockout driven by Fshr can be a valuable tool to investigate
cell non-autonomous consequences of Brca1 inactivation in the
Müllerian tract but not in the mammary gland.3.4. Epithelial Tumor Development in Mice Carrying Brca1 and p53 Double
Gene Knock Outs Driven by Mis2r and Fshr Promoters
Having characterized the distribution ofMis2r and Fshr promoter ac-
tivity in relevant tissues, we tested the hypothesis that Müllerian and
mammary tissues in mice carrying conditional Brca1 and p53 double
mutations driven by these promoters are at increased risk of malignant
Fig. 3. Distribution ofMis2r promoter activity in mouse ovaries. Gross (a) and microscopic (b) photographs of ovaries from two 2-month-oldMis2r-Cre transgenic mice crossed with the
R26RLacZ reporter strain and stained for β-Gal. The arrow indicates LacZ positive pre-ovulatory ovarian follicles. (c): Genomic DNA samples from ovarian cortex and uterine tissues were
extracted fromMis2r-Cre;R26RLacZ reporter mice 2 days before birth (E18.5) and 3 days after birth and ampliﬁed enzymatically using PCR primers speciﬁc for either the rearranged or
unrearranged β-galactosidase sequence. The PCR products were electrophoresed on 1% agarose gels containing ethidium bromide and visualized under UV. Scale bars: 200 μm.
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crossed with mice expressing either Fshr-Cre or Mis2r-Cre transgenes,
or both of these transgenes. All double-mutant mice were fertile and
had normal litter sizes. No evidence of malignancy was observed until
the mice reached 10 months old. High-grade invasive tumors startedFig. 4.Mis2r and Fshr promoter activity in the mammary gland. Mammary glands from an adu
adult R26Rmouse not carrying any transgene expressing Cre recombinase (f), and an adult Fshr
tioning of frozen tissues with a cryostat (b–e). The tissue sections were counterstained with nu
panels d and e respectively. Magniﬁcation bars: 100 μm in b, otherwise 200 μm.appearing at this time point in either mammary epithelium or in
extra-uterine Müllerian epithelium. Representative examples of such
tumors are shown in Fig. 5.
The frequency of mammary tumors based on themutational state of
Brca1 and p53 and on the nature of the transgenic construct utilized isltMis2r-Hsp68-lacZ (a–b) mouse, a newborn (day 0)Mis2r-Cre;R26RLacZ mouse (c–e), an
-Cre;R26RLacZmouse (g) were stained for LacZ either as wholemounts (a, f–g) or after sec-
clear fast red. The arrows labeled D and E in panel c indicate glands that are magniﬁed in
Fig. 5.Malignant transformation of mammary and extra-uterine Müllerian epithelium. An example of an invasive epithelial tumor of the mammary gland in a Mis2r-Cre;Fshr-
Cre;Brca1ﬂox/ﬂox;p53ﬂox/ﬂox mouse is shown in a. Different histological patterns of mammary tumors, including a solid tumor with spindloid features and a tumor showing tubular struc-
tures are shown in b and c respectively. (d): Inﬁltration of skeletal muscle by sheets of tumor cells. (e): High magniﬁcation of a solid tumor illustrating several classical features of ma-
lignant transformation including pleomorphic nuclei, atypical mitoses (thin arrow), and multinucleation (thick arrow). (f): Papillary tumor lining a pelvic extra-ovarian/extra-uterine
cyst in a Mis2r-Cre;Fshr-Cre;Brca1ﬂox/ﬂox;p53ﬂox/ﬂox mouse. Another papillary Müllerian tumor is shown in g. All tissues are stained with hematoxylin and eosin. Magniﬁcation bars:
50 μm in e, otherwise 100 μm.
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tations in both of these genes developed such tumors. The majority of
the tumors showed a solid pattern,with no evidence of acinar or tubular
formation (Fig. 5a,b,e). Cancer-speciﬁc features readily apparent inTable 1
Effect of genotype on the frequency of mammary tumors.
Number of mice with tumors/number of mice examin
(age when tumor was ﬁrst detected)a
Promoter FshrMis2r Fshr
p53 −/−;Brca1 −/− 16/26
(13.8 ± 3.22 months)
2/5
(14.5 ± 1.5 m
p53 −/−;Brca1 +/+ 6/9
(15.4 ± 1.96 months)
0/3
(n/a)
p53 +/−;Brca1 −/− 5/14
(16.3 ± 4.09 months)
4/8
(22.00 ± 3.46
p53 −/−;Brca1 +/− 3/9
(14.00 ± 1.63 months)
0/3
(n/a)
p53 +/−;Brca1 +/− 6/20
(17.7 ± 4.68 months)
0/7
(n/a)
p53 +/−;Brca1 +/+ 0/9
(n/a)
0/9
(n/a)
Wild type 0/9
(n/a)
0/9
(n/a)
a Age at which a palpable mammary tumor was ﬁrst detected in living mice.Fig. 5e include nuclear pleomorphism, atypical mitoses (thin arrow)
and multinucleation (thick arrow). All tumors, regardless of genotype,
showed high nuclear grade. In some tumors, the cells showed a
spindloid appearance (Fig. 5b). Only 4 tumors showed tubulared
Mis2r Total
onths)
1/1
(10 months)
19/32
(13.7 ± 3.13 months)
2/4
(17.0 ± 1.00 months)
8/16
(15.9 ± 1.88 months)
months)
3/4
(20.7 ± 2.49 months)
12/26
(19.3 ± 4.38 months)
0/1
(n/a)
3/13
(14.00 ± 1.63 months)
1/2
(18 months)
7/29
(17.7 ± 4.33 months)
0/7
(n/a)
0/25
(n/a)
0/3
(n/a)
0/21
(n/a)
Table 2
Effect of genotype on the frequency of Müllerian tumors.
Number of mice with tumors/number of mice examined
(age when tumor-bearing mouse was euthanized)a
Promoter Fshr Mis2r Fshr Mis2r Total
p53 −/−;Brca1 −/− 2/26
(18.0 ± 6.00 months)
0/5
(n/a)
0/1
(n/a)
2/32
(18.0 ± 6.00 months)
p53 −/−;Brca1 +/+ 0/9
(n/a)
0/3
(n/a)
0/4
(n/a)
0/16
(n/a)
p53 +/−;Brca1 −/− 0/14
(n/a)
0/8
(n/a)
0/4
(n/a)
0/26
(n/a)
p53 −/−;Brca1 +/− 0/9
(n/a)
0/3
(n/a)
0/1
(n/a)
0/13
(n/a)
p53 +/−;Brca1 +/− 0/20
(n/a)
0/7
(n/a)
1/2
(18 months)
1/29
(18 months)
p53 +/−;Brca1 +/+ 0/9
(n/a)
0/9
(n/a)
0/7
(n/a)
0/25
(n/a)
Wild type 0/9
(n/a)
0/9
(n/a)
0/3
(n/a)
0/21
(n/a)
a Age at which tumors were discovered incidentally at necropsy, including in a mouse that had reached the age of 24 months (accounting for one case), in a mouse that needed to be
euthanized because of general signs of distress (one case), and in a mouse in which a mammary tumor had become palpable (one case).
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all mammary tumors contained some tubular structures within other-
wise primarily solid lesions. No histological pattern was exclusive for
any of the Brca1 or p53 mutational states. The invasive nature of the
mammary lesions is illustrated in Fig. 5d, which shows inﬁltration of ad-
jacent skeletal muscle by cancer cells.
The frequency of extra-uterineMüllerian tumors (Table 2) was sub-
stantially lower than that of mammary tumors, presumably due in part
to the larger size of mammary glands compared to extra-uterine
Müllerian structures, but also because mice with mammary tumorsFig. 6.Morphological evidence for an origin of extra-uterine tumors from endosalpingiosis. (a)
rectangle ismagniﬁed in b. The sections show an invasive tumor surrounding the oviducts, but n
tissue that shows crowded glands lined by atypical epithelial cells. d: prominent focus of endosa
niﬁcation bars: 50 μm.were euthanized within 3 weeks of these tumors becoming grossly no-
ticeable, preventing subsequent transformation of Müllerian epitheli-
um. Mammary tumors were seen in mice harboring either the Mis2r
or the Fshr transgenic promoters, alone or in combination (Table 1),
butMüllerian tumors were not seen inmice harboring only the truncat-
ed Fshr transgenic promoter (Table 2), as expected given the lack of ex-
pression of this promoter in Müllerian epithelium as reported earlier
(Chodankar et al., 2005). This underscores the potential utility of using
mice in which Cre-mediated Brca1 rearrangements are driven by this
promoter to examine cell non-autonomous mechanisms of cancer: sections of the distal oviducts, corresponding to the human ﬁmbriae. The area within the
ot involving theﬁmbrial epithelium. (c): focus of endosalpingiosis in peri-ovarian adipose
lpingiosis in peri-ovarian adipose tissue, as typically seen inmicewithmutant Brca1. Mag-
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was not conﬁned to the fallopian tube, but included endosalpingiosis as
evidenced from the photographs in Fig. 6, which show invasive tumors
at the periphery of an otherwise intact fallopian tube (Fig. 6a-b) as well
as a transformed focus of endosalpingiosis within peri-ovarian adipose
tissue (Fig. 6c). In addition, mice in which no evidence of malignancy
was detected in Müllerian organs commonly showed prominent
endosalpingiosis (Fig. 6d). All extra-uterineMüllerian tumorswere pap-
illary and morphologically compatible with high grade serous carcino-
mas (Fig. 5f-g).
A substantial proportion (50%) of mice with a homozygous p53mu-
tation carrying a functional Brca1 allele also developed tumors, implying
that some of the cancers observed in the double mutant micemay have
been driven primarily by the mutant p53 allele. The ages at which tu-
mors developed in p53 single knockout mice were not statistically dif-
ferent than in double knockouts (P2-tailed unpaired student t-test = 0.1142,
95% conﬁdence interval from−4.849 to 0.556). However, the inﬂuence
of a mutant Brca1 allele is underscored by the fact that although 46% of
mice carrying a heterozygous p53 mutation and a homozygous Brca1
mutation developed malignancies, there was no tumor seen in mice
heterozygous for a p53mutation and wild type for Brca1 (P b 0.0001).
Thus, the presence of a Brca1mutationwas clearly instrumental in driv-
ing mammary tumors in double heterozygous mutants, which more
closely mimic the genetic background of human BRCA1 mutation car-
riers. Twenty eight percent of mice carrying heterozygous mutations
in both, p53 and Brca1 developed either a mammary or an extra-
uterine Müllerian tumor, providing a convenient level of penetrance
to investigate environmental and cell non-autonomous risk factors for
their human counterparts. The ages at which either p53+/−;Brca1+/+
or p53+/−;Brca1+/−mice developed tumors were signiﬁcantly higher
than for p53−/−;Brca1−/− mice (P2-tailed unpaired student t-test = 0.0004
and 0.02, respectively, conﬁdence intervals from −8.437 to −2.725
and−7.321 to−0.687), presumably reﬂecting the need for additional
genetic alterations, such as loss of the wild type p53 and Brca1 alleles
via loss of heterozygosity (see below) for malignant transformation.
3.5. Pelvic Tumors Other Than in Extra-uterine Müllerian Epithelium
The promoters used to drive Cre recombinase in our mouse studies
were not only expressed in mammary tissues and in extra-uterine
Müllerian epithelium, but also in ovarian follicles, renal collecting sys-
tem, and endometrium, at least at speciﬁc time points during embryo-
logical development or adult life (Figs. 1-3). Any of these tissues could
potentially carry an elevated risk of cancer development in this mouse
model. Indeed, 2 mice developed endometrial tumors that hadFig. 7. Loss of heterozygosity on chromosome 11 in amammary tumor from amouse heterozyg
mammary tumor (cancer cells) of the same mouse were ampliﬁed by PCR using ﬂuorescent pr
11. Admixed normal cells accounted for approximately one third of the total cell population in
electrophoresis using an ABI 3500 Genetic Analyzer. The tracings show 2 alleles, of respective
140 and 141 base pairs respectively. The 142 base pair allele, as well as the corresponding sh
loss of heterozygosity. These studies were repeated with 2 additional tumors and showed simremained conﬁned to the endometrium in our entire mouse cohort.
None of the mice developed tumors of either ovarian follicles or renal
ducts, underscoring the importance of cell-nonautonomous factors in
determining risk of malignant transformation.
3.6. Second Mutational Event in Mice Carrying a Germline Heterozygous
Mutation is Acquired via Loss of Heterozygosity
Most cancers that develop in human BRCA1mutation carriers harbor
mutations in both alleles of this gene. The ﬁrst mutation is acquired
through the germline while the second is usually acquired via loss of
heterozygosity, a commonmechanismof tumor suppressor gene inacti-
vation in general. We sought to determine whether a similar mecha-
nism was associated with cancer development in mice carrying
heterozygous Brca1 or p53 mutations in order to further evaluate the
merit of this model as a tool to investigate human disease. DNAwas ex-
tracted frommammary tumors of 3 different mice heterozygous for the
ﬂoxed Brca1 allele as well as from the tail of the same animals. Matched
tail and tumor DNA samples were enzymatically ampliﬁed using
primers for the Ch11qB3 locus, a dinucleotide repeat microsatellite on
mouse chromosome 11, which harbors both, the p53 and Brca1 loci.
The primers were conjugated to a ﬂuorescence-emitting chemical,
allowing determination of the size of the PCR products following capil-
lary electrophoresis. We suspected that the maternal and paternal al-
leles of microsatellite repeats might have different sizes given the
mixed genetic background of the animals used to create this model. In-
deed, 2 PCR products with major bands of respective sizes of 142 and
143 base pairs were seen in tail DNA from all 3 mice, as shown in the
representative example in Fig. 7. Shadow bands of respective sizes of
140 and 141 base pairs are also present. The reduction in the intensity
of the 142-base pair allele in DNA extracted from the tumor indicates
loss of heterozygosity.
3.7. Sex Steroid Hormone Receptor and Her-2/neu Expression Status of
Mammary Tumors
Breast cancers associated with the Brca1 mutation carrier state in
human are typically “triple negative” referring to their lack of expres-
sion of estrogen and progesterone receptors and absence of Her-2/neu
ampliﬁcation. We therefore examined the hormone receptor status of
the mammary tumors seen in mice with either p53 single knockouts
or p53/Brca1 double knockouts. Fig. 8 shows immunohistochemical
stains for estrogen (top panels) and progesterone (bottom panels) re-
ceptors on 3 randomly selected mammary tumors for which frozen tis-
sue samples were available, including 2 from mice carrying double p53ous for theﬂoxed Brca1 allele. DNA samples extracted from the tail (normal cells) or from a
imers for the Ch11qB3 locus, a dinucleotide repeat polymorphism located on chromosome
the section of tumor. The PCR products were separated based on their sizes by capillary
sizes of 142 and 143 base pairs in DNA extracted from normal cells, with 2 shadow bands
adow band of 140 base pairs, is decreased in DNA extracted from the tumor, indicating
ilar results (not shown).
Fig. 8. Presence of estrogen and progesterone receptor proteins inmammary tumors from single versus doublemutant mice. Three representative frozen sections of tumors derived from
either a p53mutant (#691) or 2 p53/Brca1 doublemutants (#939 and #2721)were stainedwith antibodies directed against either estrogen (top panels) or progesterone (bottompanels)
receptor proteins. Cre recombinase was driven by both theMis2r and the Fshr transgenic promoters in all cases. Bars: 30 μm.
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carrying only a p53mutation (case #691).Wewere unable to obtain re-
liable stains on the remaining tumors, which had been ﬁxed in formalin.
The results show no evidence of estrogen receptor immunoreactivity in
the tumors from double mutants while both, nuclear and cytoplasmic
staining was present in the tumor from the mouse carrying a single
knockout (Fig. 8). Progesterone receptor immunoreactivity was not
seen in one of the 2 tumors derived from a double mutant mouse
(#939) although it was detected in scattered tumor cells from the re-
maining such example shown in Fig. 8 (#2721). The tumor obtainedFig. 9. Levels of Her-2/neu protein in mammary tumors. Protein extracts were obtained
fromMCF-7 cells derived fromahumanbreast carcinoma lackingHer-2/neu ampliﬁcation,
frommouse muscle tissue (negative control), and from the 3 mammary carcinomas used
in Fig. 8. The protein samples were analyzed byWestern blotting using antibodies speciﬁc
for Her-2/neu and Gapdh as well as for their respective human counterparts.from a p53 single mutant stained strongly for progesterone receptor)
(Fig. 8).
Protein extracts were also obtained from the same tumors and ex-
amined for Her-2/neu expression by Western blotting (Fig. 9). Expres-
sion of this protein was detected in all 3 tumors. The amount of
expression was not higher than that seen in MCF-7 mammary carcino-
ma cells inwhich this oncogene is not ampliﬁed.We conclude that none
of the 3 tumors show Her-2/neu ampliﬁcation.
4. Discussion
We took advantage of 2 promoters with largely overlapping, but
slightly different cell speciﬁcity to introduce conditional Brca1 and p53
double knockouts targeting the mammary gland, reproductive organs,
and also organs playing a central role in controlling the estrous cycle,
which is equivalent to the human menstrual cycle. The important
drivers of estrous cycle activity targeted in this experimental model in-
clude ovarian granulosa cells and a subset of cells within the anterior pi-
tuitary. We had previously reported that Brca1 inactivation in ovarian
granulosa cells leads to changes in estrous cycle dynamics including
prolongation of the pre-ovulatory phase and increased circulating levels
of sex steroid hormones (Hong et al., 2010) and also reported on evi-
dence that alterations in these hormonal levels are also present in
human BRCA1 mutation carriers (Widschwendter et al., 2013). Given
the well-established importance of menstrual cycle activity as a risk
modulator for breast and extra-uterine Müllerian carcinomas, our in-
tentionwas to generate amousemodel suitable to investigate the inter-
play between genetic and hormonal factors of predisposition to both of
these cancers. The truncated form of the Fshr promoter that we used in
our studies is active in ovarian granulosa cells and in the anterior
pituitary, both of which inﬂuence Müllerian tumorigenesis in a cell-
nonautonomous manner, but it is not expressed in Müllerian epitheli-
um (Chodankar et al., 2005). Thus, any contribution of genetic
alterations driven by this promoter to Müllerian carcinogenesis can
only be mediated through a cell-nonautonomous mechanism, hence
its importance in our overall strategy.
Several transgenic or knockout models for extra-uterine Müllerian/
ovarian and for mammary carcinomas have been developed over the
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Hasan et al., 2015) for reviews). In some cases, speciﬁc pathways, in-
cluding Her-2/neu in mammary epithelium, Pten in Müllerian epitheli-
um, and others have been targeted while others have focused on Brca1/
2 inactivation in tissues corresponding to those with an elevated cancer
risk in human BRCA1/2mutation carriers. These contributions led to sig-
niﬁcant progress in our understanding of the cell-autonomous role of
speciﬁc pathways in the development of these cancers. The model de-
scribed here is associated with tumors that are morphologically similar
to the human tumors associated with the BRCA1/2 mutation carrier
state, as evidenced by the high-grade papillary serous appearance of
Müllerian tumors and the basal appearance and triple negative nature
of at least some of the mammary tumors that we observed. This
model is not based on targeting any speciﬁc signaling pathway, but on
the inactivation of cell cycle regulators associatedwith humanmamma-
ry and extra-uterine Müllerian cancer predisposition. It is also distin-
guished from existing models based on the following features: (1) it
not only targets tissues similar to those at elevated risk of cancer in
human BRCA1/2mutation carriers, but also organs that inﬂuence cancer
predisposition from a distance via cell-nonautonomous mechanisms,
closely mimicking the conditions associated with cancer predisposition
in human BRCA1mutation carriers; (2) the fact that a signiﬁcant propor-
tion of mice heterozygous for Brca1 and p53mutations develop tumors
further increases similarities to the genetic background associated with
human familial breast and extra-uterine Müllerian cancer predisposi-
tion; (3) the possibility of generating tumors in mice that are heterozy-
gous for a Brca1 mutation avoids confounders due to developmental
defects associated with homozygous deletions of different splice forms
of this gene, which have been reported both in the mammary gland
and in the reproductive tract (Xu et al., 1999; Kim et al., 2006); (4) dif-
ferences in the tissue speciﬁcity of the various promoters used to drive
tissue-speciﬁc mutations, plus the possibility of using surgical manipu-
lations entailing ovarian transplantation betweenmutant andwild type
donors, make it possible to study cell-autonomous and the cell-
nonautonomous mechanisms of cancer predisposition independently
of each other and, therefore, to distinguish their respective contribu-
tions. Cell-nonautonomous mechanisms, which are mediated by circu-
lating factors as opposed to intra-cellular changes, should be readily
targetable pharmacologically, hence the importance of understanding
their exact mechanisms.
Cell-autonomous and -nonautonomous effects in the mammary
gland cannot be distinguished from each other simply by using different
combinations of the Mis2r and Fshr promoters because both of these
promoters are active in mammary epithelium. However, the fact that
the Fshr promoter leads to cell-nonautonomous effects as previously
documented (Chodankar et al., 2005; Hong et al., 2010; Yen et al.,
2012) implies that mammary tumors are inﬂuenced by both mecha-
nisms in the presence of both promoters, in contrast to existing models
based on cell-autonomous strategies. Isolation of the cell-autonomous
and cell-nonautonomous effects in order to investigate their relative
roles is possible by performing ovarian transplantations from mutant
donors into wild type recipients and vice versa, as we have done previ-
ously (Hong et al., 2010).
Mice carrying a mutation in p53 but not in Brca1 also developed
mammary tumors, raising questions about the contribution of the
Brca1mutation to cancer development in our double mutant animals.
However, while mice carrying heterozygous mutations in both genes
developed mammary tumors, none of the mice carrying only a hetero-
zygous p53 mutation developed such tumors, demonstrating that
Brca1 mutations are instrumental in driving tumor development in
this model.
Three different groups have previously attempted to develop animal
models for extra-uterine Müllerian carcinoma predisposition based on
conditional knockouts of Brca1 and p53 driven in part by theMis2r pro-
moter (Clark-Knowles et al., 2009; Quinn et al., 2009; Xing et al., 2009).
These investigators showed a high incidence rate ofMüllerian sarcomasin the doublemutantmice, but did not report on the presence of any ep-
ithelial tumor. In contrast, a single sarcoma was seen in our mouse co-
horts, in a mouse carrying a p53mutation and wild type Brca1. In 2 of
those previous studies (Clark-Knowles et al., 2009; Quinn et al., 2009),
the mutant mice carried deletions targeting a larger number of the
exons of Brca1 than in our mouse model that only targeted exon 11.
However, this is unlikely to fully account for the phenotypic differences
observed with these models because not only was the ﬂoxed Brca1 al-
lele used by Xing et al. (2009) identical to the one used in our studies,
but also these authors used a transgenic construct driven by the Mis2r
promoter to induce Brca1 recombination. It is possible that differences
in the nature of theMis2r-Cre construct used by Xing et al., which was
based on a knock-in strategy in contrast to our studies, may have led
to differences in levels of promoter activity.
Our characterization of the tissue distribution ofMis2r promoter ac-
tivity, led to the unexpected ﬁnding that a segment of the renal tubules,
more speciﬁcally tubules located in the deep cortical area, show evi-
dence of pastMis2r activity limited to females. These ﬁndings strongly
suggest that a portion of the renal tubular system is embryologically
linked to theMüllerian ducts, as supported by imaging studies of devel-
oping embryos reported by Kobayashi et al. (2003). The fact that differ-
ent signalingmolecules and transcription factors, such as Lim, Pax2, and
WT1, are important regulators of both renal and Müllerian duct devel-
opment provides further evidence for a link between these 2 organs
(Mueller, 1994; Torres et al., 1995; Grote et al., 2006; Orvis and
Behringer, 2007). This conclusion is also supported by the observation
that congenital disorders associated with unilateral renal aplasia are
often associated with absence of fallopian tube on the same side and
unicornuate uterus on the other side (Grunwald, 1941). The presence
of a developmental, embryological link between the Müllerian ducts
and renal tubules may help explain gender differences in kidney func-
tion in health and disease, which is a topic of great current interest in
renal (patho)physiology (Reckelhoff and Maric, 2010). These ﬁndings
also have implications for the origin of the clear cell subtype of extra-
uterineMüllerian carcinomas. All other major subtypes of these tumors
can be readily associated with an extra-uterine Müllerian epithelial
structure of a similar differentiation lineage (Dubeau, 2008). Tumors be-
longing to the clear cell subtype not only show morphological resem-
blances to clear cell carcinomas of the kidneys, but also their gene
expression proﬁle has been reported to share similarities with that of
these tumors (Zorn et al., 2005). These cancers also share similarities
in their response to chemotherapy (Anglesio et al., 2011). The adult
(metanephros) and fetal (mesonephros) kidneys are both derived
from the pronephric duct (Pole et al., 2002; Pietila and Vainio, 2005).
In addition, themesonephric ureteric bud is a driver ofmetanephros de-
velopment (Sainio et al., 1997), underscoring an embryological link be-
tween the mesonephros and metanephros. Different signaling
molecules and transcription factors, such as Lim, Pax2, andWT1, are im-
portant regulators of both renal and Müllerian duct development
(Mueller, 1994; Torres et al., 1995; Grote et al., 2006; Orvis and
Behringer, 2007), providing further evidence for a link between these
2 organs. We therefore propose that mesonephric remnants, which
are abundant in the para-ovarian and para-tubal areas, should be
regarded as integral components of extra-uterine Müllerian epithelium
and may play a role in the histogenesis of clear cell carcinomas.
Our ﬁndings have implications on the site of origin of serous extra-
uterine Müllerian carcinomas, which until recently were thought to
originate primarily frommetaplastic fociwithin the ovarian surfaceme-
sothelium (Dubeau, 1999, 2008). The fallopian tube is currently
regarded as the most important site of origin of these tumors, the
type associated with the BRCA1 mutation carrier state. We argued
earlier that other extra-uterine Müllerian structures, including
endosalpingiosis, endometriosis, and endocervicosis are also important
in the histogenesis of the serous, endometrioid, andmucinous subtypes,
respectively (Dubeau, 1999, 2008; Ahmed et al., 2010; Dubeau and
Drapkin, 2013). All pelvic tumors seen in our mouse cohort appeared
1329Y. Liu et al. / EBioMedicine 2 (2015) 1318–1330to have originated from endosalpingiosis, indicating that such extra-
uterine structures are at risk of cancer development in mice carrying
mutations mimicking those present in human with familial extra-
uterine Müllerian carcinoma in support of our hypothesis.
In summary, we developed a mouse model that recapitulates the
cell-autonomous and cell-nonautonomous mechanisms of cancer pre-
disposition in human BRCA1 carriers. This model should facilitate eluci-
dation of the menstrual factors associated with cell-nonautonomous
mechanisms, which could represent attractive targets for cancer pre-
vention strategies. Characterization of this model led to insights into
the role of endosalpingiosis in the histogenesis of high grade serous
extra-uterineMüllerian tumors, previously called ovarian,which should
be considered in developing early detection and risk-reducing surgical
strategies for these tumors. Our ﬁndings also shed light on the differen-
tiation lineage of Müllerian clear cell carcinomas, which may facilitate
the development of novel therapeutic approaches.
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